MKI67 and breast cancer: However, because of the uniformly low rate of pCR and slow response, NCT was not suggested as the preferred option for rapidly reducing the stage of large tumor burdens.40-42 They also reported that higher pretreatment Ki67 was more likely to attain pCR after NCT and that higher pretreatment Ki67 may improve the prognostic significance of clinical response in NCT.43-45 Our study showed that patients with TNBC experienced significantly higher pCR than those with hormone-receptor positive BC.